American Association for Cancer Research
23266066cir170258-sup-183547_2_supp_4349335_sycfs7.pdf (408.23 kB)

Supplemental Figure 4 from Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity

Download (408.23 kB)
journal contribution
posted on 2023-04-03, 23:01 authored by Karla R. Wiehagen, Natasha M. Girgis, Douglas H. Yamada, Andressa A. Smith, Szeman Ruby Chan, Iqbal S. Grewal, Michael Quigley, Raluca I. Verona

S4. The cytokine milieu is more inflammatory in anti-CD40 and combination treated tumors.



Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with agonist anti-CD40 treatment confers superior antitumor efficacy and increased survival compared with monotherapy treatment in preclinical tumor models. Concurrent CSF-1R blockade and CD40 agonism lead to profound changes in the composition of immune infiltrates, causing an overall decrease in immunosuppressive cells and a shift toward a more inflammatory milieu. Anti-CD40/anti–CSF-1R–treated tumors contain decreased tumor-associated macrophages and Foxp3+ regulatory T cells. This combination approach increases maturation and differentiation of proinflammatory macrophages and dendritic cells and also drives potent priming of effector T cells in draining lymph nodes. As a result, tumor-infiltrating effector T cells exhibit improved responses to tumor antigen rechallenge. These studies show that combining therapeutic approaches may simultaneously remove inhibitory immune populations and sustain endogenous antitumor immune responses to successfully impair cancer progression. Cancer Immunol Res; 5(12); 1109–21. ©2017 AACR.

Usage metrics

    Cancer Immunology Research



    Ref. manager